期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
卷 18, 期 16, 页码 6129-6144出版社
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.74951
关键词
BMAL1; GPAM; EZH2; lipid biosynthesis; growth; metastasis; hepatocellular carcinoma
资金
- National Natural Science Foundation of China
- Young Elite Scientist Program by CAST
- Natural Science Foundation of Shaanxi Province
- [81772934]
- [81772618]
- [81802345]
- [2018QNRC001]
- [2020JM-327]
The down-regulation of BMAL1 is associated with poor survival in HCC patients, and it promotes HCC cell growth and metastasis by suppressing the expression of GPAM and reducing LPA levels. The activator of BMAL1, SR8278, exhibits therapeutic effects on HCC, highlighting the potential of BMAL1 as a target for HCC therapy.
The circadian clock confers daily rhythmicity to many crucial biological processes and behaviors and its disruption is closely associated with carcinogenesis in several types of cancer. Brain and muscle arnt-like protein 1 (BMAL1) is a core circadian rhythm component in mammals and its dysregulation has been shown to contribute to aberrant metabolism in human diseases. However, the biological functions of BMAL1, especially its involvement in aberrant lipid metabolism in hepatocellular carcinoma (HCC), remain elusive. In the present study, we found that BMAL1 was frequently down-regulated in HCC cells mainly due to the up-regulation of miR-494-3p. Down-regulation of BMAL1 was significantly associated with poor survival in HCC patients. BMAL1 down-regulation promoted HCC cell growth and metastasis both in vitro and in vivo. Mechanistically, through cooperating with EZH2, BMAL1 transcriptionally suppressed the expression of glycerol-3-phosphate acyltransferase mitochondrial (GPAM), a key enzyme involved in the regulation of lipid biosynthesis, leading to reduced levels lysophosphatidic acid (LPA), which have long been known as mediator of oncogenesis. Particularly, treatment with SR8278, an activator of BMAL1, exhibited a therapeutic effect on HCC in vitro and in vivo. In conclusion, BMAL1 plays a critical anti-oncogenic role in HCC, providing strong research evidence for BMAL1 as a prospective target for HCC therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据